Michael L Jackson1, Jennifer C Nelson. 1. Group Health Research Institute. 1730 Minor Ave, Suite 1600, Seattle, WA 98101-1448, United States. jackson.ml@ghc.org
Abstract
OBJECTIVE: The test-negative design has emerged in recent years as the preferred method for estimating influenza vaccine effectiveness (VE) in observational studies. However, the methodologic basis of this design has not been formally developed. METHODS: In this paper we develop the rationale and underlying assumptions of the test-negative study. Under the test-negative design for influenza VE, study subjects are all persons who seek care for an acute respiratory illness (ARI). All subjects are tested for influenza infection. Influenza VE is estimated from the ratio of the odds of vaccination among subjects testing positive for influenza to the odds of vaccination among subjects testing negative. RESULTS: With the assumptions that (a) the distribution of non-influenza causes of ARI does not vary by influenza vaccination status, and (b) VE does not vary by health care-seeking behavior, the VE estimate from the sample can generalized to the full source population that gave rise to the study sample. Based on our derivation of this design, we show that test-negative studies of influenza VE can produce biased VE estimates if they include persons seeking care for ARI when influenza is not circulating or do not adjust for calendar time. CONCLUSIONS: The test-negative design is less susceptible to bias due to misclassification of infection and to confounding by health care-seeking behavior, relative to traditional case-control or cohort studies. The cost of the test-negative design is the additional, difficult-to-test assumptions that incidence of non-influenza respiratory infections is similar between vaccinated and unvaccinated groups within any stratum of care-seeking behavior, and that influenza VE does not vary across care-seeking strata.
OBJECTIVE: The test-negative design has emerged in recent years as the preferred method for estimating influenza vaccine effectiveness (VE) in observational studies. However, the methodologic basis of this design has not been formally developed. METHODS: In this paper we develop the rationale and underlying assumptions of the test-negative study. Under the test-negative design for influenza VE, study subjects are all persons who seek care for an acute respiratory illness (ARI). All subjects are tested for influenza infection. Influenza VE is estimated from the ratio of the odds of vaccination among subjects testing positive for influenza to the odds of vaccination among subjects testing negative. RESULTS: With the assumptions that (a) the distribution of non-influenza causes of ARI does not vary by influenza vaccination status, and (b) VE does not vary by health care-seeking behavior, the VE estimate from the sample can generalized to the full source population that gave rise to the study sample. Based on our derivation of this design, we show that test-negative studies of influenza VE can produce biased VE estimates if they include persons seeking care for ARI when influenza is not circulating or do not adjust for calendar time. CONCLUSIONS: The test-negative design is less susceptible to bias due to misclassification of infection and to confounding by health care-seeking behavior, relative to traditional case-control or cohort studies. The cost of the test-negative design is the additional, difficult-to-test assumptions that incidence of non-influenza respiratory infections is similar between vaccinated and unvaccinated groups within any stratum of care-seeking behavior, and that influenza VE does not vary across care-seeking strata.
Authors: Joshua G Petrie; Caroline Cheng; Ryan E Malosh; Jeffrey J VanWormer; Brendan Flannery; Richard K Zimmerman; Manjusha Gaglani; Michael L Jackson; Jennifer P King; Mary Patricia Nowalk; Joyce Benoit; Anne Robertson; Swathi N Thaker; Arnold S Monto; Suzanne E Ohmit Journal: Clin Infect Dis Date: 2015-11-12 Impact factor: 9.079
Authors: Michael L Jackson; Lisa A Jackson; Burney Kieke; David McClure; Manjusha Gaglani; Kempapura Murthy; Ryan Malosh; Arnold Monto; Richard K Zimmerman; Ivo M Foppa; Brendan Flannery; Mark G Thompson Journal: Vaccine Date: 2015-08-11 Impact factor: 3.641
Authors: Suzanne E Ohmit; Mark G Thompson; Joshua G Petrie; Swathi N Thaker; Michael L Jackson; Edward A Belongia; Richard K Zimmerman; Manjusha Gaglani; Lois Lamerato; Sarah M Spencer; Lisa Jackson; Jennifer K Meece; Mary Patricia Nowalk; Juhee Song; Marcus Zervos; Po-Yung Cheng; Charles R Rinaldo; Lydia Clipper; David K Shay; Pedro Piedra; Arnold S Monto Journal: Clin Infect Dis Date: 2013-11-13 Impact factor: 9.079
Authors: Kate Russell; Jessie R Chung; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard K Zimmerman; Mary Patricia Nowalk; Michael L Jackson; Lisa A Jackson; Brendan Flannery Journal: Vaccine Date: 2018-02-28 Impact factor: 3.641
Authors: Jill M Ferdinands; Manjusha Gaglani; Emily T Martin; Don Middleton; Arnold S Monto; Kempapura Murthy; Fernanda P Silveira; H Keipp Talbot; Richard Zimmerman; Elif Alyanak; Courtney Strickland; Sarah Spencer; Alicia M Fry Journal: J Infect Dis Date: 2019-09-13 Impact factor: 5.226
Authors: Huong Q McLean; Herve Caspard; Marie R Griffin; Manjusha Gaglani; Timothy R Peters; Katherine A Poehling; Christopher S Ambrose; Edward A Belongia Journal: JAMA Netw Open Date: 2018-10-05
Authors: Andrea S Gershon; Hannah Chung; Joan Porter; Michael A Campitelli; Sarah A Buchan; Kevin L Schwartz; Natasha S Crowcroft; Aaron Campigotto; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; J Dayre McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Andrew E Simor; Marek Smieja; George Zahariadis; Jeffrey C Kwong Journal: J Infect Dis Date: 2020-01-01 Impact factor: 5.226
Authors: Mark G Thompson; Jessie Clippard; Joshua G Petrie; Michael L Jackson; Huong Q McLean; Manjusha Gaglani; Evelyn C Reis; Brendan Flannery; Arnold S Monto; Lisa Jackson; Edward A Belongia; Kempapura Murthy; Richard K Zimmerman; Swathi Thaker; Alicia M Fry Journal: Pediatr Infect Dis J Date: 2016-03 Impact factor: 2.129